Today we announced that three abstracts on intismeran autogene, our investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (@myESMO) Congress 2026, which will be held October 23–27 in Madrid, Spain. Read more: feeds.issuerdirect.com/news-… #ESMO26

Read our latest press release: feeds.issuerdirect.com/news-…

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applications for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. Read more: feeds.issuerdirect.com/news-…

Read our latest press release: accessnewswire.com/newsroom/…

Along with our partners at @Merck, we announced positive results from the Phase 3 INTerpath-001 study of intismeran autogene, our investigational individualized neoantigen therapy, in combination with pembrolizumab as adjuvant treatment in patients with completely resected Stage IIB-IV melanoma. This marks the first and only combination regimen to demonstrate a clinically meaningful improvement over pembrolizumab alone, a current standard-of-care for these patients. In our latest IR Insights, members of our executive team sat down to reflect on what this means: modernatx.com/ir-insights-ph…

Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma. Read more:

Today we announced that the U.S. Food and Drug Administration has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee supporting mFLUSIVA for adults 50 years of age and older. Read more: feeds.issuerdirect.com/news-…

Today we announced that following Health Canada’s authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, our investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus disease. Read more: feeds.issuerdirect.com/news-…

Today we reported financial results and provided business updates for the second quarter of 2026. Read more: feeds.issuerdirect.com/news-…

Today we announced the dosing of the first U.S. participant in our Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. Read more: feeds.issuerdirect.com/news-…

At Moderna, our Mission is to deliver the greatest possible impact to people through mRNA medicines. In pursuit of this, we remain focused on advancing our science, supporting our people, and delivering for patients, communities, and the environment. Our latest Impacting Human Health Report reflects how we are continuing to turn scientific progress into meaningful impact while helping shape a healthier future for people around the world. Read the full report: static.modernatx.com/pm/6cef…

Today we announced the appointment of Michael McDonnell to our Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee. Read more: feeds.issuerdirect.com/news-…

Happy Fourth of July! 🇺🇸

Yesterday, Moderna announced research and early development updates at our Science Day event. Members of our executive team sat down to provide more insight into our strategy that balances near-term growth with long-term innovation. Watch our latest IR Insights video to learn more: modernatx.com/ir-insights-sc…

At our Science Day event, we shared how we're building Moderna for the next decade and beyond. In his latest blog post, our CEO Stéphane Bancel outlines our three-horizon strategy—executing on today's commercial opportunities while advancing new modalities and investing in science, AI and platform innovation that will help shape the next generation of mRNA medicines. Read more: modernatx.com/science-day

Today we announced research and early development updates at our Science Day event. The updates include information on our strategic plan to become a diversified, multi-modality biotechnology company and balance near-term growth with long-term innovation. Read more: feeds.issuerdirect.com/news-…

We recently received authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for our Phase 1/2 clinical study evaluating mRNA-4194, an investigational mRNA-based vaccine for people with Lynch syndrome, an inherited condition that increases the risk of cancer. David Berman, our Chief Development Officer, sat down for an episode of IR Insights to provide an overview of this innovative program and Moderna’s research in the cancer prevention vaccine space: modernatx.com/media-center/a…

Today, along with the University of Oxford, we announced that a Phase 1/2 study of mRNA-4194, our investigational cancer vaccine for Lynch syndrome, has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK. The trial is part of a scientific collaboration between Moderna and the University of Oxford to advance a novel mRNA approach to cancer prevention. Read more: feeds.issuerdirect.com/news-…